In what may prove to be a minor public relations setback for vaccine pushers like Bill Gates and GlaxoSmithKline, the much touted Mosquirix malaria vaccine recently rolled out in Africa has been officially demonstrated to be only 30% effective in babies.
Results from the final-stage trial administered by GSK appeared to demonstrate that the vaccine only provided “modest protection” for babies aged six to 12 weeks, with a reduction in the contraction of the disease by only 30%, a much lower number than what had been touted by those promoting the jab in the industry and the corporate media.
Reuters also reports that for children after the age of six months, a 65% rate was established. For children of five to 17 months old, the researchers claim a protection of around 50% .... http://www.activistpost.com
